Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,571 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 27, 2026, 9:10 AM EDT
Active, not recruiting Phase 1 Interventional

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391
View directory record Official record
Conditions
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19CAR-28-zeta T cells, Ipilimumab
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

NCT04118842
View directory record Official record
Conditions
Solid Tumors
Interventions
Savolitinib, Rifampicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 27, 2026, 9:10 AM EDT
Completed No phase listed Observational

A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION

NCT03151642
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Chemotherapy, Radiation Therapy, Surgery, MRI Imaging, Blood Draws
Radiation · Procedure · Device + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

NCT07433569
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Not applicable Interventional Results available

The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS

NCT05299723
View directory record Official record
Conditions
Sleep Disturbance, Insomnia, Acute Coronary Syndrome
Interventions
BLT Intervention, BLB Intervention, Sleep Hygiene Education
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 27, 2026, 9:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nutrition and Body Composition in Acute Lymphoblastic Leukemia

NCT01317940
View directory record Official record
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Interventions
Vitamin D and Calcium Citrate
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 29 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 27, 2026, 9:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Not applicable Interventional Results available

Improvement of Patient Satisfaction and Overall Outcomes Using HealthLoop

NCT03481595
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip
Interventions
HealthLoop mobile application
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Personalized Mind-Body Intervention (MBI) for Improving Sleep Among Women Working in Healthcare

NCT05789212
View directory record Official record
Conditions
Sleep Insufficiency
Interventions
Personalized Trial ABCCBA, Personalized Trial CBAABC
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

NCT00911066
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
MLN4924, Azacitidine
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients

NCT00372411
View directory record Official record
Conditions
Stroke
Interventions
Robot-Assisted Therapy - MIT-MANUS System, Intensive Comparison Therapy, Usual Care
Device · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
West Haven, Connecticut • Gainesville, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

NCT01441232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LX4211, Januvia®
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

NCT06344728
View directory record Official record
Conditions
Healthy Participants
Interventions
Brensocatib Oral Solution, Brensocatib Oral Tablet
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women

NCT03558828
View directory record Official record
Conditions
Physical Activity
Interventions
Step 1: PA Monitor, Step 1: PA Monitor + Text, Step 2: PA Monitor with Calls, Step 2: PA Monitor with Meetings, Step 2: PA Monitor + Texts with Calls, Step 2: PA Monitor + Texts with Meetings, Step 3: PA Monitor
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

NCT02088398
View directory record Official record
Conditions
Healthy
Interventions
ACY-1215
Drug
Lead sponsor
Acetylon Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 27, 2026, 9:10 AM EDT
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 27, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 27, 2026, 9:10 AM EDT